Skip to Main Content
It looks like you're using Internet Explorer 11 or older. This website works best with modern browsers such as the latest versions of Chrome, Firefox, Safari, and Edge. If you continue with this browser, you may see unexpected results.

The Faculty of Medicine - Developmental Biology and Cancer Research: Buganim Yossi


 Last updated June 2021 - School of Pharmacy

List of Publications

(1) Kolb T, Khalid U, Simović M, Ratnaparkhe M, Wong J, Jauch A, et al. A versatile system to introduce clusters of genomic double-strand breaks in large cell populations. Genes Chromosomes Cancer 2021;60(5):303-313.

(2) Seranova E, Palhegyi AM, Verma S, Dimova S, Lasry R, Naama M, et al. Human Induced Pluripotent Stem Cell Models of Neurodegenerative Disorders for Studying the Biomedical Implications of Autophagy. J Mol Biol 2020;432(8):2754-2798.

(3) Brill-Karniely Y, Dror D, Duanis-Assaf T, Goldstein Y, Schwob O, Millo T, et al. Triangular correlation (TrC) between cancer aggressiveness, cell uptake capability, and cell deformability. Sci Adv 2020;6(3).

(4) Benchetrit H, Jaber M, Zayat V, Sebban S, Pushett A, Makedonski K, et al. Direct Induction of the Three Pre-implantation Blastocyst Cell Types from Fibroblasts. Cell Stem Cell 2019;24(6):983-994.e7.

(5) Yehuda Y, Blumenfeld B, Mayorek N, Makedonski K, Vardi O, Cohen-Daniel L, et al. Germline DNA replication timing shapes mammalian genome composition. Nucleic Acids Res 2018;46(16):8299-8310.

(6) Ward C, Volpe G, Cauchy P, Ptasinska A, Almaghrabi R, Blakemore D, et al. Fine-Tuning Mybl2 Is Required for Proper Mesenchymal-to-Epithelial Transition during Somatic Reprogramming. Cell Rep 2018;24(6):1496-1511.e8.

(7) Jaber M, Sebban S, Buganim Y. Acquisition of the pluripotent and trophectoderm states in the embryo and during somatic nuclear reprogramming. Curr Opin Genet Dev 2017;46:37-43.

(8) Maoz N, Buganim Y. Moving towards totipotency without a single miR-acle. Cell Res 2017;27(5):600-601.

(9) Masika H, Farago M, Hecht M, Condiotti R, Makedonski K, Buganim Y, et al. Programming asynchronous replication in stem cells. Nat Struct Mol Biol 2017;24(12):1132-1138.

(10) Buganim Y. Back to basics: Refined nuclear reprogramming techniques yield higher-quality stem cells. Science 2016;352(6292):1401.

(11) Cohen MA, Wert KJ, Goldmann J, Markoulaki S, Buganim Y, Fu D, et al. Human neural crest cells contribute to coat pigmentation in interspecies chimeras after in utero injection into mouse embryos. Proc Natl Acad Sci U S A 2016;113(6):1570-1575.

(12) Sebban S, Buganim Y. Nuclear Reprogramming by Defined Factors: Quantity Versus Quality. Trends Cell Biol 2016;26(1):65-75.

(13) Buganim Y. Tex10: A New Player in the Core Pluripotency Circuitry. Cell Stem Cell 2015;16(6):572-573.

(14) Benchetrit H, Herman S, Van Wietmarschen N, Wu T, Makedonski K, Maoz N, et al. Extensive Nuclear Reprogramming Underlies Lineage Conversion into Functional Trophoblast Stem-like Cells. Cell Stem Cell 2015;17(5):543-556.

(15) Buganim Y, Markoulaki S, Van Wietmarschen N, Hoke H, Wu T, Ganz K, et al. The developmental potential of iPSCs is greatly influenced by reprogramming factor selection. Cell Stem Cell 2014;15(3):295-309.

(16) Sarkar S, Carroll B, Buganim Y, Maetzel D, Ng A, Cassady JP, et al. Impaired autophagy in the lipid-storage disorder niemann-pick type c1 disease. Cell Rep 2013;5(5):1302-1315.

(17) Faddah DA, Wang H, Cheng AW, Katz Y, Buganim Y, Jaenisch R. Single-cell analysis reveals that expression of nanog is biallelic and equally variable as that of other pluripotency factors in mouse escs. Cell Stem Cell 2013;13(1):23-29.

(18) Sahay G, Querbes W, Alabi C, Eltoukhy A, Sarkar S, Zurenko C, et al. Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. Nat Biotechnol 2013;31(7):653-658.

(19) Buganim Y, Faddah DA, Jaenisch R. Mechanisms and models of somatic cell reprogramming. Nat Rev Gen 2013;14(6):427-439.

(20) Molchadsky A, Ezra O, Amendola PG, Krantz D, Kogan-Sakin I, Buganim Y, et al. P53 is required for brown adipogenic differentiation and has a protective role against diet-induced obesity. Cell Death Differ 2013;20(5):774-783.

(21) Buganim Y, Jaenisch R. Transdifferentiation by defined factors as a powerful research tool to address basic biological questions. Cell Cycle 2012;11(24):4485-4486.

(22) Kalo E, Kogan-Sakin I, Solomon H, Bar-Nathan E, Shay M, Shetzer Y, et al. Mutant p53R273H attenuates the expression of phase 2 detoxifying enzymes and promotes the survival of cells with high levels of reactive oxygen species. J Cell Sci 2012;125(22):5578-5586.

(23) Buganim Y, Faddah DA, Cheng AW, Itskovich E, Markoulaki S, Ganz K, et al. Single-cell expression analyses during cellular reprogramming reveal an early stochastic and a late hierarchic phase. Cell 2012;150(6):1209-1222.

(24) Buganim Y, Itskovich E, Hu Y-, Cheng AW, Ganz K, Sarkar S, et al. Direct reprogramming of fibroblasts into embryonic sertoli-like cells by defined factors. Cell Stem Cell 2012;11(3):373-386.

(25) Solomon H, Buganim Y, Kogan-Sakin I, Pomeraniec L, Assia Y, Madar S, et al. Various p53 mutant proteins differently regulate the ras circuit to induce a cancer-related gene signature. J Cell Sci 2012;125(13):3144-3152.

(26) Leibovich-Rivkin T, Buganim Y, Solomon H, Meshel T, Rotter V, Ben-Baruch A. Tumor-promoting circuits that regulate a cancer-related chemokine cluster: Dominance of inflammatory mediators over oncogenic alterations. Cancers 2012;4(1):55-76.

(27) Rakovitsky N, Buganim Y, Swissa T, Kinel-Tahan Y, Brenner S, Cohen MA, et al. Retraction notice to 'Drosophila Ten-a is a maternal pair-rule and patterning gene' [Mech. Dev. 124 (2007) 911-924]. Mech Dev 2012;129(1-4):73.

(28) Carey BW, Markoulaki S, Hanna JH, Faddah DA, Buganim Y, Kim J, et al. Reprogramming factor stoichiometry influences the epigenetic state and biological properties of induced pluripotent stem cells. Cell Stem Cell 2011;9(6):588-598.

(29) Tabach Y, Sakin IK, Buganim Y, Solomon H, Goldfinger N, Hovland R, et al. Amplification of the 20q chromosomal arm occurs early in tumorigenic transformation and may initiate cancer. PLoS ONE 2011;6(1).

(30) Kogan-Sakin I, Tabach Y, Buganim Y, Molchadsky A, Solomon H, Madar S, et al. Mutant p53 R175H upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells. Cell Death Differ 2011;18(2):271-281.

(31) Brosh R, Sarig R, Natan EB, Molchadsky A, Madar S, Bornstein C, et al. P53-dependent transcriptional regulation of EDA2R and its involvement in chemotherapy-induced hair loss. FEBS Lett 2010;584(11):2473-2477.

(32) Buganim Y, Solomon H, Rais Y, Kistner D, Nachmany I, Brait M, et al. p53 regulates the ras circuit to inhibit the expression of a cancer-related gene signature by various molecular pathways. Cancer Res 2010;70(6):2274-2284.

(33) Buganim Y, Goldstein I, Lipson D, Milyavsky M, Polak-Charcon S, Mardoukh C, et al. A novel translocation breakpoint within the BPTF gene is associated with a pre-malignant phenotype. PLoS ONE 2010;5(3).

(34) Solomon H, Brosh R, Buganim Y, Rotter V. Inactivation of the p53 tumor suppressor gene and activation of the Ras oncogene: cooperative events in tumorigenesis. Discov Med 2010;9(48):448-454.

(35) Aylon Y, Yabuta N, Besserglick H, Buganim Y, Rotter V, Nojima H, et al. Silencing of the lats2 tumor suppressor overrides a p53-dependent oncogenic stress checkpoint and enables mutant H-Ras-driven cell transformation. Oncogene 2009;28(50):4469-4479.

(36) Buganim Y, Rotter V. p53: Balancing tumour suppression and implications for the clinic. Eur J Cancer 2009;45(SUPPL. 1):217-234.

(37) Kogan-Sakin I, Cohen M, Paland N, Madar S, Solomon H, Molchadsky A, et al. Prostate stromal cells produce CXCL-1, CXCL-2, CXCL-3 and IL-8 in response to epithelia-secreted IL-1. Carcinogenesis 2009;30(4):698-705.

(38) Madar S, Brosh R, Buganim Y, Ezra O, Goldstein I, Solomon H, et al. Modulated expression of WFDC1 during carcinogenesis and cellular senescence. Carcinogenesis 2009;30(1):20-27.

(39) Brosh R, Shalgi R, Liran A, Landan G, Korotayev K, Nguyen GH, et al. p53-repressed miRNAs are involved with E2F in a feed-forward loop promoting proliferation. Mol Syst Biol 2008;4.

(40) Buganim Y, Rotter V. RHAMM in the complex p53 cell cycle network. Cell Cycle 2008;7(21):3287-3291.

(41) Kalo E, Buganim Y, Shapira KE, Besserglick H, Goldfinger N, Weisz L, et al. Mutant p53 attenuates the SMAD-dependent transforming growth factor β1 (TGF-β1) signaling pathway by repressing the expression of TGF-β receptor type II. Mol Cell Biol 2007;27(23):8228-8242.

(42) Rakovitsky N, Buganim Y, Swissa T, Kinel-Tahan Y, Brenner S, Cohen MA, et al. Drosophila Ten-a is a maternal pair-rule and patterning gene. Mech Dev 2007;124(11-12):911-924.

(43) Tabach Y, Brosh R, Buganim Y, Reiner A, Zuk O, Yitzhaky A, et al. Wide-scale analysis of human functional transcription factor binding reveals a strong bias towards the transcription start site. PLoS ONE 2007;2(8).

(44) Milyavsky M, Shats I, Cholostoy A, Brosh R, Buganim Y, Weisz L, et al. Inactivation of Myocardin and p16 during Malignant Transformation Contributes to a Differentiation Defect. Cancer Cell 2007;11(2):133-146.

(45) Buganim Y, Kalo E, Brosh R, Besserglick H, Nachmany I, Rais Y, et al. Mutant p53 protects cells from 12-O-tetradecanoylphorbol-13-acetate-induced death by attenuating activating transcription factor 3 induction. Cancer Res 2006;66(22):10750-10759.

(46) Milyavsky M, Tabach Y, Shats I, Erez N, Cohen Y, Tang X, et al. Transcriptional programs following genetic alterations in p53, INK4A, and H-Ras genes along defined stages of malignant transformation. Cancer Res 2005;65(11):4530-4543.